CASP1 and metabolic dysfunction-associated steatohepatitis: Recent studies have shown that Exenatide treatment can effectively reduce the expression of NLRP3, caspase-1, and IL-1β in OA/LPS-induced HepG2 cells and MCD-induced db/db mouse livers, which in turn inhibits the pyroptosis signaling pathway to alleviate NASH [96].